1. Pink Sheet
  2. >>Compliance

Need For Advanced Manufacturing Technologies A ‘Great Learning’ From The Pandemic, CBER’s Marks Says

 
• By Sue Sutter

COVID-19 highlighted limited domestic capacity and need for more flexibility, agility and reliability in manufacturing processes, says FDA biologics center director Peter Marks; he also discussed differences in data review for vaccine BLAs relative to EUAs.  

Classroom
Limited capacity and agility in domestic manufacturing sites is one of CBER director Peter Marks' lessons learned from the pandemic. • Source: Alamy

Implementing advanced manufacturing techniques before the next pandemic will enable speedier ramp-up of vaccines for emerging infectious diseases and could broadly benefit the regenerative medicine field, the head of the US Food and Drug Administration’s biologics center believes.

“I would be remiss if I didn’t share with you one of my great learnings from this pandemic and that is our country, I think for our national security, for our global health security, needs to think more about manufacturing

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Manufacturing

More from Compliance